Search Results - "Di Fiore, Frederic"

Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study) by Garlan, Fanny, Laurent-Puig, Pierre, Sefrioui, David, Siauve, Nathalie, Didelot, Audrey, Sarafan-Vasseur, Nasrin, Michel, Pierre, Perkins, Geraldine, Mulot, Claire, Blons, Hélène, Taieb, Julien, Di Fiore, Frederic, Taly, Valerie, Zaanan, Aziz

“…Markers of chemotherapy efficacy in metastatic colorectal cancer (mCRC) are essential for optimization of treatment strategies. We evaluated the applicability…”
Get full text

Predictive value of initial FDG-PET features for treatment response and survival in esophageal cancer patients treated with chemo-radiation therapy using a random forest classifier by Desbordes, Paul, Ruan, Su, Modzelewski, Romain, Pineau, Pascal, Vauclin, Sébastien, Gouel, Pierrick, Michel, Pierre, Di Fiore, Frédéric, Vera, Pierre, Gardin, Isabelle

“…In oncology, texture features extracted from positron emission tomography with 18-fluorodeoxyglucose images (FDG-PET) are of increasing interest for predictive…”
Get full text

The Day after Tomorrow: How Should We Address Health System Organization to Treat Cancer Patients after the Peak of the COVID-19 Epidemic? by Tuech, Jean-Jacques, Gangloff, Alice, Di Fiore, Frederic, Benyoucef, Ahmed, Michel, Pierre, Schwarz, Lilian

“…On March 11, 2020, the WHO director general declared COVID-19 a pandemic. This pandemic evolves in successive phases, i.e., phase 1 (the start phase), phase 2…”
Get more information

Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trial – Prodige 31 REMINET: An FFCD study by Lepage, Côme, Phelip, Jean-Marc, Lievre, Astrid, Le-Malicot, Karine, Dahan, Laetitia, Tougeron, David, Toumpanakis, Christos, Di-Fiore, Frédéric, Lombard-Bohas, Catherine, Borbath, Ivan, Coriat, Romain, Lecomte, Thierry, Guimbaud, Rosine, Petorin, Caroline, Legoux, Jean-Louis, Michel, Pierre, Scoazec, Jean-Yves, Smith, Denis, Walter, Thomas

“…Following European guidelines, patients with aggressive metastatic or locally advanced, non-resectable, duodeno-pancreatic (DP) neuroendocrine tumours…”
Get full text

Impact of new generation hormone-therapy on cognitive function in elderly patients treated for a metastatic prostate cancer: Cog-Pro trial protocol by Lange, Marie, Laviec, Heidi, Castel, Hélène, Heutte, Natacha, Leconte, Alexandra, Léger, Isabelle, Giffard, Bénédicte, Capel, Aurélie, Dubois, Martine, Clarisse, Bénédicte, Coquan, Elodie, Di Fiore, Frédéric, Gouérant, Sophie, Bartélémy, Philippe, Pierard, Laure, Fizazi, Karim, Joly, Florence

“…New generation hormone-therapies (NGHT) targeting the androgen signalling pathway are nowadays proposed to elderly patients with metastatic…”
Get full text

Beyond atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: overall efficacy and safety of tyrosine kinase inhibitors in a real-world setting by Falette-Puisieux, Manon, Nault, Jean-Charles, Bouattour, Mohamed, Lequoy, Marie, Amaddeo, Giuliana, Decaens, Thomas, Di Fiore, Frederic, Manfredi, Sylvain, Merle, Philippe, Baron, Aurore, Locher, Christophe, Pellat, Anna, Coriat, Romain

“…Background: In patients with advanced hepatocellular carcinoma (HCC) progressing after atezolizumab and bevacizumab, the optimal therapeutic sequence is still…”
Get full text

Prognostic Value of Circulating Mutant DNA in Unresectable Metastatic Colorectal Cancer by LEFEBURE, Benoit, CHARBONNIER, Françoise, DI FIORE, Frederic, JACQUES TUECH, Jean, LE PESSOT, Florence, MICHOT, Françis, MICHEL, Pierre, FREBOURG, Thierry

“…No validated biologic prognostic marker is presently available in metastatic colorectal cancer (MCRC). We prospectively evaluated the prognostic value of…”
Get full text

Colorectal cancer chemoprevention: is aspirin still in the game? by Grancher, Adrien, Michel, Pierre, Di Fiore, Frederic, Sefrioui, David

“…Screening strategies have demonstrated their potential for decreasing the incidence and mortality of cancers, particularly that of colorectal cancer (CRC)…”
Get full text

TERT Promoter Alterations in Glioblastoma: A Systematic Review by Olympios, Nathalie, Gilard, Vianney, Marguet, Florent, Clatot, Florian, Di Fiore, Frédéric, Fontanilles, Maxime

“…Glioblastoma, the most frequent and aggressive primary malignant tumor, often presents with alterations in the telomerase reverse transcriptase promoter…”
Get full text

Impact of FcγRIIa-FcγRIIIa Polymorphisms and KRAS Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan by BIBEAU, Frédéric, LOPEZ-CRAPEZ, Evelyne, SABOURIN, Jean-Christophe, BOISSIERE-MICHOT, Florence, DI FIORE, Frédénc, THEZENAS, Simon, YCHOU, Marc, BLANCHARD, France, LAMY, Aude, PENAULT-LLORCA, Frédérique, FREBOURG, Thierry, MICHEL, Pierre

“…Purpose The antiepidermal growth factor receptor antibody cetuximab shows activity in irinotecan-refractory metastatic colorectal cancer (mCRC), mainly in…”
Get full text

Bevacizumab plus FOLFIRI after failure of platinum–etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trial by Walter, Thomas, Lievre, Astrid, Coriat, Romain, Malka, David, Elhajbi, Farid, Di Fiore, Fréderic, Hentic, Olivia, Smith, Denis, Hautefeuille, Vincent, Roquin, Guillaume, Perrier, Marine, Dahan, Laetitia, Granger, Victoire, Sobhani, Iradj, Mineur, Laurent, Niccoli, Patricia, Assenat, Eric, Scoazec, Jean-Yves, Le Malicot, Karine, Lepage, Côme, Lombard-Bohas, Catherine

“…There is no standard second-line treatment after platinum–etoposide chemotherapy for gastroenteropancreatic neuroendocrine carcinoma. We aimed to evaluate the…”
Get full text

Where do we stand with screening for colorectal cancer and advanced adenoma based on serum protein biomarkers? A systematic review by Grancher, Adrien, Cuissy, Steven, Girot, Hélène, Gillibert, André, Di Fiore, Frédéric, Guittet, Lydia

“…Colorectal cancer (CRC) screening has been proven to reduce both mortality and the incidence of this disease. Most CRC screening programs are based on fecal…”
Get full text

Circulating PIK3CA mutation detection at diagnosis in non-metastatic inflammatory breast cancer patients by Allouchery, Violette, Perdrix, Anne, Calbrix, Céline, Berghian, Anca, Lequesne, Justine, Fontanilles, Maxime, Leheurteur, Marianne, Etancelin, Pascaline, Sarafan-Vasseur, Nasrin, Di Fiore, Frédéric, Clatot, Florian

“…Inflammatory breast cancer (IBC) is an aggressive BC subtype with poor outcomes. A targetable somatic PIK3CA mutation is reported in 30% of IBC, allowing for…”
Get full text

Circulating ESR1 mutations at the end of aromatase inhibitor adjuvant treatment and after relapse in breast cancer patients by Allouchery, Violette, Beaussire, Ludivine, Perdrix, Anne, Sefrioui, David, Augusto, Laetitia, Guillemet, Cécile, Sarafan-Vasseur, Nasrin, Di Fiore, Frédéric, Clatot, Florian

“…Detection of circulating ESR1 mutations is associated with acquired resistance to aromatase inhibitor (AI) in metastatic breast cancer. Until now, the presence…”
Get full text

Circulating DNA changes are predictive of disease progression after transarterial chemoembolization by Sefrioui, David, Verdier, Vincent, Savoye‐Collet, Céline, Beaussire, Ludivine, Ghomadi, Slim, Gangloff, Alice, Goria, Odile, Riachi, Ghassan, Montialoux, Hélène, Schwarz, Lilian, Tuech, Jean‐Jacques, Frebourg, Thierry, Michel, Pierre, Sarafan‐Vasseur, Nasrin, Di Fiore, Frédéric

“…Transarterial chemoembolization (TACE) is used to treat patients with unresectable hepatocellular carcinoma (HCC). We evaluated the clinical impact of…”
Get full text

Prognostic value of sarcopenia in patients treated by Radiochemotherapy for locally advanced oesophageal cancer by Mallet, Romain, Modzelewski, Romain, Lequesne, Justine, Mihailescu, Sorina, Decazes, Pierre, Auvray, Hugues, Benyoucef, Ahmed, Di Fiore, Fréderic, Vera, Pierre, Dubray, Bernard, Thureau, Sébastien

“…Sarcopenia is defined by a loss of skeletal muscle mass with or without loss of fat mass. Sarcopenia has been associated to reduced tolerance to treatment and…”
Get full text

Clinical relevance of circulating ESR1 mutations during endocrine therapy for advanced hormone-dependent endometrial carcinoma by Drouyer, Aurélien, Beaussire, Ludivine, Jorda, Pauline, Leheurteur, Marianne, Guillemet, Cécile, Berghian, Anca, Georgescu, Dragos, Di Fiore, Frédéric, Perdrix, Anne, Clatot, Florian

“…Abstract Objective Endocrine therapy is frequently administered in patients with hormone dependent (HR+) metastatic endometrial cancer. ESR1 mutations have…”
Get full text

Short report: Monitoring ESR1 mutations by circulating tumor DNA in aromatase inhibitor resistant metastatic breast cancer by Sefrioui, David, Perdrix, Anne, Sarafan‐Vasseur, Nasrin, Dolfus, Claire, Dujon, Antoine, Picquenot, Jean‐Michel, Delacour, Julien, Cornic, Marie, Bohers, Elodie, Leheurteur, Marianne, Rigal, Olivier, Tennevet, Isabelle, Thery, Jean‐Christophe, Alexandru, Cristina, Guillemet, Cécile, Moldovan, Cristian, Veyret, Corinne, Frebourg, Thierry, Di Fiore, Frédéric, Clatot, Florian

“…Acquired estrogen receptor gene (ESR1) mutations have been recently reported as a marker of resistance to aromatase inhibitors in hormone receptor positive…”
Get full text

Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer by Clatot, Florian, Perdrix, Anne, Beaussire, Ludivine, Lequesne, Justine, Lévy, Christelle, Emile, George, Bubenheim, Michael, Lacaille, Sigrid, Calbrix, Céline, Augusto, Laetitia, Guillemet, Cécile, Alexandru, Cristina, Fontanilles, Maxime, Sefrioui, David, Burel, Lucie, Guénot, Sabine, Richard, Doriane, Sarafan-Vasseur, Nasrin, Di Fiore, Frédéric

“…Endocrine therapy is recommended as a first-line treatment for hormone receptor-positive metastatic breast cancer (HR+MBC) patients. No biomarker has been…”
Get full text

Impact of Taxanes, Endocrine Therapy, and Deleterious Germline BRCA Mutations on Anti-müllerian Hormone Levels in Early Breast Cancer Patients Treated With Anthracycline- and Cyclophosphamide-Based Chemotherapy by Lambertini, Matteo, Olympios, Nathalie, Lequesne, Justine, Calbrix, Céline, Fontanilles, Maxime, Loeb, Agnès, Leheurteur, Marianne, Demeestere, Isabelle, Di Fiore, Frédéric, Perdrix, Anne, Clatot, Florian

“…Limited evidence exists on the impact of adding a taxane, using endocrine therapy and carrying a deleterious germline mutation on ovarian reserve measured by…”
Get full text